Cancer – SiAlpha – Investment Institute

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP

ZIOPHARM Oncology, Inc., a bio pharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant Glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression […]

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP Read More »

News: Biocept Launched Liquid Biopsy Test $BIOC

Healthcare, News / Research Team

Biocept, Inc., a molecular diagnostics company, has launched liquid Biopsy test for Breast and Lungs Cancer. It will help physicians identify patients who may be receptive to certain breast and lung cancer treatments. “The launch of FGFR1 testing is part of our strategy to use liquid biopsy to transform the field of personalized medicine,” said Raaj Trivedi,

News: Biocept Launched Liquid Biopsy Test $BIOC Read More »

Advaxis to Sale Common Stock $ADXS $XHS

Healthcare / Research Team

Advaxis Inc, has announced to issue a total of 45,000,000 Common shares of at value of $0.001 per share, and 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share. The Net Proceeds from above would be around $200 Million. View the full release here.

Advaxis to Sale Common Stock $ADXS $XHS Read More »